(Q53890584)

22 May 2018

title

125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. (English)

1 reference

22 May 2018

multicenter clinical trial

main subject

1 reference

3

Lawrence True

1 reference

22 May 2018

author name string

Kent Wallner

1

1 reference

22 May 2018

Gregory Merrick

2

1 reference

22 May 2018

Steven Sutlief

4

1 reference

22 May 2018

William Cavanagh

5

1 reference

22 May 2018

Wayne Butler

6

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 December 2003

1 reference

22 May 2018

International Journal of Radiation Oncology Biology Physics

published in

1 reference

22 May 2018

volume

57

1 reference

22 May 2018

issue

5

1 reference

22 May 2018

page(s)

1297-1303

1 reference

22 May 2018

Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Isotope selection for patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Long-term complications with prostate implants: iodine-125 vs. palladium-103.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

A reappraisal of local anesthesia for prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Follow-up costs after external radiation for low risk prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Anticipating prostatic volume changes due to prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

How low is the alpha/beta ratio for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

The effect of interobserver differences in post-implant prostate CT image interpretation on dosimetric parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Interpretation of pre- versus postimplant TRUS images

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Prostate brachytherapy seed identification on post-implant TRUS images

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

Isodose patterns in patients with inadequate prostate brachytherapy coverage

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2901448-2

7 January 2021

10.1016/S0360-3016(03)01448-2

Identifiers

DOI

1 reference

22 May 2018

release_il7ntgo54zbdfgn2acgetp7upu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/il7ntgo54zbdfgn2acgetp7upu

24 November 2022

mapped directly with Wikidata item

1 reference

22 May 2018